{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:38:27Z","timestamp":1793176707065,"version":"4.5.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.<\/jats:p>","DOI":"10.4103\/0019-5154.143574","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T03:05:15Z","timestamp":1414551915000},"page":"632-632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Remission of Psoriasis and Psoriatic Arthritis During Bevacizumab Therapy for Renal Cell Cancer"],"prefix":"10.4103","volume":"59","author":[{"given":"Ananaya","family":"Datta-Mitra","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, School of Medicine, Davis, CA 95616, USA"},{"name":"Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, VA Medical Centre Sacramento, Mather, CA 95655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep K","family":"Riar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hospital Medicine, University of California Davis, School of Medicine, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, School of Medicine, Davis, CA 95616, USA"},{"name":"Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, VA Medical Centre Sacramento, Mather, CA 95655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-141-2-200407200-00027","article-title":"Angiogenesis therapy moves beyond cancer","volume":"141","author":"Wilson","year":"2004","journal-title":"Ann Intern Med"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","article-title":"Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J Exp Med"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.0022-202X.2003.22107.x","article-title":"Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset","volume":"122","author":"Young","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00365510410003732","article-title":"Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis","volume":"64","author":"Gudbjornsson","year":"2004","journal-title":"Scand J Clin Lab Invest"},{"key":"R5-20250921","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1365-2133.1999.03205.x","article-title":"Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis","volume":"141","author":"Bhushan","year":"1999","journal-title":"Br J Dermatol"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2230.2008.02991.x","article-title":"Complete remission of psoriasis following bevacizumab therapy for colon cancer","volume":"34","author":"Akman","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R7-20250921","first-page":"321","article-title":"Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis","volume":"19","author":"Lee","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1006\/bbrc.2001.4395","article-title":"Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice","volume":"281","author":"Sone","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10456-007-9081-1","article-title":"Angiogenesis as a therapeutic target in arthritis: Learning the lessons of the colorectal cancer experience","volume":"10","author":"Khong","year":"2007","journal-title":"Angiogenesis"},{"key":"R10-20250921","first-page":"208606","article-title":"Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma","volume":"2012","author":"Graceffa","year":"2012","journal-title":"Case Rep Rheumatol"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"e89960","DOI":"10.1371\/journal.pone.0089960","article-title":"An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.4103\/0019-5154.152543","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000}}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201459060-00040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:24Z","timestamp":1787067744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201459060-00040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-5154.143574","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}